Abstract: The subject invention concerns a novel selective, sensitive, and highly reliable immunoassay for detecting human IL-1&bgr; in cultured mononuclear cells or human body fluids. It is a competitive immunoassay which is useful in diagnostic work to detect IL-1&bgr; selectively, for the first time, from among similar lymphokines and other substances known to interfere with bioassays for IL-1.

Abstract: The composition formed by mixing an organosilane, optionally having a nonhydrolizable organic group, but having one or more hydrolyzable groups, with a polyol containing at least two hydroxy groups, wherein at least any two of the hydroxy groups are separated by no more than two intervening atoms. Water-stabilized organosilane compounds. A water stable composition made from the polyol and organosilane or compound and water. A method of treating a substrate by mixing or contacting the substrate with the product compound, or composition of this invention for a period of time sufficient for treatment of the substrate. A treated substrate having adhered thereto the product, compound, or composition of this invention. A method of dyeing and treating a substrate. A method of antimicrobially treating a food article. A method of antimicrobially coating a fluid container. A method of antimicrobially coating a latex medical article. A method of making a siloxane in the presence of a stabilizer.

Abstract: The subject invention provides a method for diagnosing prostate cancer and determining preoperatively the pathological stage in patients with prostate cancer. The methods described herein can be used for prediction of margin positivity, seminal vesicle (S.V.) involvement, and lymph nodal (L.N.) involvement in patients with clinically localized prostate cancer. The method includes use of a neural network which provides prostate cancer stage information for a patient based upon input data which includes the patient's preoperative serum PSA, biopsy Gleason score, and systemic biopsy-based information. Its positive predictive value (PPV), negative predictive value (NPV), and accuracy are superior to that of current nomograms in use. Use of this method can result in enormous cost savings by accurately diagnosing patients with prostate cancer and by avoiding multiple imaging tests and expensive surgery in unindicated patients.